Purespring Therapeutics

Executive Summary

Purespring Therapeutics is a preclinical-stage gene therapy company developing a novel AAV-based platform to treat kidney diseases by directly targeting podocytes, the key filtering cells of the kidney. Founded in 2020 and headquartered in Cambridge, MA, the company has raised $175 million to advance its pipeline. Its initial focus is on rare genetic kidney disorders, with the potential to expand into broader chronic kidney disease (CKD) indications. The proprietary approach aims to restore podocyte function or introduce protective factors, addressing a critical unmet need in nephrology. With no approved gene therapies for kidney diseases, Purespring's platform could be a first-in-class modality, leveraging decades of AAV research adapted to the unique challenges of kidney delivery. The company is currently in preclinical development, and its success hinges on demonstrating proof-of-concept in animal models and advancing toward clinical trials. Given the substantial funding and the novelty of the approach, Purespring represents a high-risk, high-reward opportunity in the gene therapy space.

Upcoming Catalysts (preview)

• Q3 2026IND Submission for lead program in rare genetic kidney disease70% success
• Q4 2026Preclinical proof-of-concept data in chronic kidney disease model60% success
• Q2 2026Potential strategic partnership or licensing deal for platform technology50% success